Histology
Invasive Carcinoma
CI-CAN-00001040Explore in graph →
603 active trials9 approved drugs37 evidence items
- NCIt
- C9480
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001040Explore in graph →
Clinical trials
1,812 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01970722 | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | active not recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06028932 | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | active not recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06268665 | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | recruiting | Phase 2 | 86 | University of California, DavisOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07445308 | The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG. | not yet recruiting | Phase 1 / Phase 2 | 120 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 0 | Mar 3, 2026 | clinicaltrials |
| NCT04943536 | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer(BiolenRT) | active not recruiting | Phase 1 | 20 | Alessa Therapeutics Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02296229 | Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer | active not recruiting | N/A | 220 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04897009 | Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer(ENHANCE) | active not recruiting | — | 38 | Mayo ClinicOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07432594 | Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer | not yet recruiting | Phase 2 | 82 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT03414970 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer | active not recruiting | Phase 3 | 898 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 24, 2026 | clinicaltrials |
| NCT07285057 | Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | recruiting | Phase 2 | 120 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04997096 | Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07421479 | Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01)(PDO-Mercurial) | active not recruiting | — | 50 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06470282 | Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 47 | University of California, San FranciscoOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06744465 | NearWave Optical Molecular Monitoring | recruiting | N/A | 15 | Indiana UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07234968 | Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy | recruiting | N/A | 70 | Thomas Jefferson UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03862677 | Determining Prognostic Immune Markers in Patients With Ovarian Cancer(IMPrOVE) | recruiting | — | 300 | Leiden University Medical CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05683964 | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | active not recruiting | Early Phase 1 | 9 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05316181 | CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)(KOV-HIPEC-02R) | active not recruiting | Phase 3 | 140 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04781088 | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 38 | Floor Backes, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05383196 | Onvansertib + Paclitaxel In TNBC | active not recruiting | Phase 1 / Phase 2 | 50 | Antonio Giordano, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04368702 | CONFIRM: Magnetic Resonance Guided Radiation Therapy(CONFIRM) | recruiting | N/A | 70 | Brigham and Women's HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05937620 | Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer(Melisa-II) | recruiting | N/A | 62 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04704505 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)(BAT-RAD) | recruiting | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 6, 2026 | clinicaltrials |
| NCT03902951 | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | active not recruiting | Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04455750 | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy(CASPAR) | active not recruiting | Phase 3 | 61 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05737199 | Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma | active not recruiting | Phase 2 | 21 | Niigata University Medical & Dental HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07276438 | Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial | recruiting | N/A | 186 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03296826 | Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 | recruiting | — | 600 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06469281 | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers | recruiting | Phase 1 | 90 | Regeneron PharmaceuticalsINDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07280312 | Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions | recruiting | N/A | 40 | Mayo ClinicOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05806515 | Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04734730 | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | recruiting | Phase 2 | 70 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05129969 | Registry Platform Ovarian and Endometrial Cancer(SMARAGD) | recruiting | — | 1,975 | iOMEDICO AGINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04959474 | Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer | recruiting | N/A | 80 | Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04871516 | Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer | active not recruiting | N/A | 103 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05693766 | Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort(INSIGHT) | recruiting | Phase 2 | 64 | Sonya ReidOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06666439 | Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer(LBC-Monitor) | recruiting | — | 20 | Julia FoldiOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03367702 | Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer | active not recruiting | Phase 3 | 692 | NRG OncologyOTHER | 6 | Jan 15, 2026 | clinicaltrials |
| NCT04448886 | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | active not recruiting | Phase 2 | 110 | Ana C Garrido-Castro, MDOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07339761 | Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study(SPICE) | recruiting | N/A | 30 | University of AarhusOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06328465 | fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases(fREEDOM) | recruiting | N/A | 145 | European Institute of OncologyOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07080944 | Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC(SYMPHONY) | recruiting | N/A | 75 | European Institute of OncologyOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03344965 | Olaparib In Metastatic Breast Cancer | active not recruiting | Phase 2 | 114 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05023967 | Metformin and Nightly Fasting in Women With Early Breast Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT05962541 | Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)(CUT-less) | recruiting | Phase 4 | 327 | University of Roma La SapienzaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 5, 2026source: clinicaltrials